Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ADA 2021 June 25 - 29

Incorporating Treatment Pauses, Dosing Flexibility, And Education To Support GLP-1RA Therapy Persistence

Vanita R. Aroda1; Robert Bauer2; Alun Lloyd Davies2; Eskil Brandt Kreiner2; Peter Lin3; Richard Pratley4; Stephen Bain5;
1 Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2 Novo Nordisk A/S, Søborg, Denmark; 3 Canadian Heart Research Centre, North York, Ontario, Canada; 4 AdventHealth Translational Research Institute, Orlando, FL, USA; 5 Diabetes Research Unit, Swansea University Medical School, Swansea, UK;